Literature DB >> 24403304

Isavuconazole treatment of a patient with disseminated mucormycosis.

Driele Peixoto1, Lisa S Gagne, Sarah P Hammond, Erin T Gilmore, Amy C Joyce, Robert J Soiffer, Francisco M Marty.   

Abstract

We report a patient with relapsed acute myelogenous leukemia after allogeneic stem cell transplantation who developed disseminated mucormycosis due to Rhizomucor pusillus/R. miehei involving lung, brain, and skin. After failing posaconazole and being intolerant to amphotericin, he was treated effectively with isavuconazole for over 6 months despite ongoing treatment for relapsed leukemia.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24403304      PMCID： PMC3957744          DOI： 10.1128/JCM.03176-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis.

Authors:  M Reinwald; L Uharek; D Lampe; T Grobosch; E Thiel; S Schwartz
Journal:  Bone Marrow Transplant       Date:  2009-02-16       Impact factor: 5.483

2.  Posaconazole concentrations in the central nervous system.

Authors:  Maria J G T Rüping; Nadine Albermann; Friedrich Ebinger; Irene Burckhardt; Claudia Beisel; Carsten Müller; Jörg J Vehreschild; Matthias Kochanek; Gerd Fätkenheuer; Christopher Bangard; Andrew J Ullmann; Wolfgang Herr; Karin Kolbe; Michael Hallek; Oliver A Cornely
Journal:  J Antimicrob Chemother       Date:  2008-09-28       Impact factor: 5.790

Review 3.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

4.  PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue.

Authors:  R Bialek; F Konrad; J Kern; C Aepinus; L Cecenas; G M Gonzalez; G Just-Nübling; B Willinger; E Presterl; C Lass-Flörl; V Rickerts
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 5.  Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.

Authors:  Alessandro C Pasqualotto; Karoline O Thiele; Luciano Z Goldani
Journal:  Curr Opin Investig Drugs       Date:  2010-02

6.  Molecular methods to improve diagnosis and identification of mucormycosis.

Authors:  Sarah P Hammond; Ralf Bialek; Danny A Milner; Eva M Petschnigg; Lindsey R Baden; Francisco M Marty
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

Review 7.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

8.  Successful isavuconazole salvage therapy in a patient with invasive mucormycosis.

Authors:  J Ervens; M Ghannoum; B Graf; S Schwartz
Journal:  Infection       Date:  2013-11-12       Impact factor: 3.553

Review 9.  New and emerging treatments for fungal infections.

Authors:  A C Pasqualotto; D W Denning
Journal:  J Antimicrob Chemother       Date:  2008-01       Impact factor: 5.790

10.  In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.

Authors:  Jesús Guinea; Teresa Peláez; Sandra Recio; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.938
View more
  22 in total

1.  Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.

Authors:  Anuradha Chowdhary; Pradeep Kumar Singh; Shallu Kathuria; Ferry Hagen; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

2.  Isavuconazole Diffusion in Infected Human Brain.

Authors:  Claire Rouzaud; Vincent Jullien; Anne Herbrecht; Bruno Palmier; Simona Lapusan; Marjolaine Morgand; Romain Guéry; Amélie Dureault; François Danion; Stéphanie Puget; Lauriane Goldwirt; Fanny Lanternier; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole.

Authors:  Jose F Camargo; Danny Yakoub; Jeong Hee Cho-Vega
Journal:  Mycopathologia       Date:  2015-06-26       Impact factor: 2.574

4.  Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT.

Authors:  Martin Schmidt-Hieber; Dan Engelhard; Andrew Ullmann; Per Ljungman; Johan Maertens; Rodrigo Martino; Montserrat Rovira; Peter J Shaw; Christine Robin; Maura Faraci; Jenny Byrne; Kerstin Schäfer-Eckart; Hermann Einsele; Edgar Faber; Luigi Rigacci; Riccardo Saccardi; Aitana Balaguer-Rosello; Cecilia Isaksson; Maximilian Christopeit; Gloria Tridello; Junfeng Wang; Nina Knelange; Malgorzata Mikulska; Simone Cesaro; Jan Styczynski
Journal:  J Neurol       Date:  2019-10-29       Impact factor: 4.849

5.  Isavuconazole as salvage therapy for mucormycosis.

Authors:  Bianca Graves; C Orla Morrissey; Andrew Wei; John Coutsouvelis; Samantha Ellis; Alan Pham; Julian Gooi; Michelle Ananda-Rajah
Journal:  Med Mycol Case Rep       Date:  2016-03-08

Review 6.  Role of isavuconazole in the treatment of invasive fungal infections.

Authors:  Dustin T Wilson; V Paul Dimondi; Steven W Johnson; Travis M Jones; Richard H Drew
Journal:  Ther Clin Risk Manag       Date:  2016-08-03       Impact factor: 2.423

7.  CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  M Schmidt-Hieber; G Silling; E Schalk; W Heinz; J Panse; O Penack; M Christopeit; D Buchheidt; U Meyding-Lamadé; S Hähnel; H H Wolf; M Ruhnke; S Schwartz; G Maschmeyer
Journal:  Ann Oncol       Date:  2016-04-06       Impact factor: 32.976

Review 8.  Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.

Authors:  Suganthini Krishnan Natesan; Pranatharthi H Chandrasekar
Journal:  Infect Drug Resist       Date:  2016-12-07       Impact factor: 4.003

9.  Extrapolating Antifungal Animal Data to Humans - Is it reliable?

Authors:  Victoria M Stevens; Scott W Mueller; Paul M Reynolds; Robert MacLaren; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16

10.  Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.

Authors:  Anne-Hortense Schmitt-Hoffmann; Kota Kato; Robert Townsend; Michael J Potchoiba; William W Hope; David Andes; Jochen Spickermann; Marlowe J Schneidkraut
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.